Cannabis is the most commonly used drug worldwide. However, there is limited understanding of factors supporting cannabis use (CU) and the development of cannabis use disorder (CUD). There is also a clear association between mood disorders and CUD, but the mechanism underlying this relationship is unclear. There is evidence that major depression is associated with elevated monoamine oxidases (MAO). Tobacco use is also associated with an inhibition of MAOs (both subtype A and B). Our hypothesis is that the same inhibition is happening in the brain of people exposed to cannabis.
Current cancer immunotherapies, although highly successful, are complex to implement, costly, and only effective in small patient populations with specific cancer types. We propose to overcome these problems by developing small molecules to induce immunogenic cell death (ICD), a cancer cell death process that engages the immune system to recognize and eliminate cancer cells and to generate immunological memory. Cuprous Pharmaceuticals Inc. (CPI) has identified ICD-inducing compounds that are enhanced by copper (Cu) as an adjuvant.
Nutraceuticals are being used ubiquitously, but seldom undergo rigorous testing. This study is focused on two primary aspects of studying natural health products, specific cannabis and its oils. The first objective is to determine the shelf life (product stability) by performing a series of tests to accelerate the ageing process in order to provide an estimation of shelf life. Currently, cannabis oils have arbitrary assignments of expiry dates, if at all. The other key focus involves studying the antioxidant benefits (or pro-oxidant detriment) imparted by cannabis products.
To design effective and patient-specific cancer therapy, sensitive detection of relapse and distant metastases by non-invasive medical imaging is essential, for which MRI offers tremendous potential due to wide availability of the equipment in clinic and avoidance of ionizing radiation. Although gadolinium-based contrast agents are the most frequently used for MRI, they are associated with nephrogenic systemic fibrosis and brain deposition. Thus, less toxic manganese ions (Mn 2+ ) are exploited as an alternative for tumor detection using MRI.
Huntington’s Disease (HD) is a fatal hereditary neurodegenerative disease caused by expansion of the CAG repeat tract at the 5’ of the huntingtin (htt) gene resulting in polyglutamine expansion of the HTT protein (polyQ-HTT) of aberrant function. HD symptoms include loss of motor coordination, cognitive and speech impairment, and psychiatric disorders. HD affects approximately 1 in 7000 people in Canada, and there are no cures or disease-modifying therapies to date.
A new therapy was developed in order to combat cancers by stimulating our immune system to fight agents the cancer cells in the body. The activated immune system is more efficient to fight the cancer cells than the common drugs, but stimulating the immune system is very expensive and labour-intensive with the currently developed protocols. This project will develop a cost-effective way to stimulate immune system to fight cancers. We will use advanced biomaterials and immune stimulatory genes in order to achieve this.
Making sure patients have well controlled post-operative pain is imperative for patient well-being, optimal recovery, and to prevent chronic pain from developing. Opioid medications are often used to treat post-surgical pain, but some people respond in unpredictable ways and this may be related to their genetics. Pharmacogenetic (PGx) testing is a way of finding out how people’s genes affect the way they respond to medications.
Older adults are the largest growing segment of the Canadian population. Almost 40% of men and 59% of women aged 65 to 79 years experience sleep disturbances. Non-pharmacological interventions, such as educational programs and exercise, can improve quality of life of older individuals by enhancing sleep quality. Although strong evidence suggests that virtual reality (VR) programs are effective for improving mood, memory, and cognitive performance, little is known about the effect of VR exercises on sleep quality.
Drugs that block muscarinic receptors are able to enhance nerve repair in various diseases of the peripheral nervous system. In collaboration with WinSanTor Inc based in San Diego, USA, the laboratory of Dr. Paul Fernyhough at University of Manitoba now plans to develop novel peptide antagonists that also block the muscarinic receptor. These peptides will provide new intellectual property and permit testing of efficacy to prevent disease in animal models of neuropathy.
Opioid-related harms such as abuse, misuse, addiction, diversion and overdose have been rising exponentially, a phenomenon referred to as the opioid epidemic. The current research will examine federal and provincial risk minimization measures (RMMs) regarding the opioid epidemic starting in 2016. We will develop a landscape of federal and provincial opioid RMMs, describe trends over time in the number and types of RMMs, assess the association between RMMs and public awareness and the association between RMMs and opioid-related harms.